Zevra Therapeutics Provides Update On Regulatory Submission For Arimoclomol
ZVRA•Regulatory update on arimoclomol
July 24 (Reuters) - Zevra Therapeutics Inc (ZVRA.O):
- Zevra Therapeutics provides update on regulatory submission for arimoclomol for the treatment of Niemann-Pick disease type C (NPC) in the European Union.
- Zevra Therapeutics said the CHMP adopted a negative opinion on the arimoclomol MAA for Niemann-Pick disease type C.
- Zevra Therapeutics said it will request re-examination of the CHMP opinion on arimoclomol.
Source text: ID:nGNX9hcgpK
